Merck Acquiring Peloton Therapeutics Pushing to Diversify Offerings In Cancer

By John Heerdink LinkedIn

Merck & Co., Inc.  (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some the of the world’s most challenging diseases for more than a century.  They are committed to increasing health care access and continue to be at the leading edge of research.

Merck announced this week that is acquiring Dallas based Peloton Therapeutics Inc. for $1.05 billion in cash and $1.15 billion in additional payments tagged to how well their experimental development proceeds.

Reportedly, Merck’s Chief Executive Officer Ken Frazier stated in a conference in April that the company was looking for mid-sized deals to help diversify its market offering, especially targeting cancer treatment. Peloton’s primary area of research is the treatment of Kidney Cancer seems to clearly check the box in this regard for the drug maker.

Credit Suisse and Centerview Partners are representing Merck and Peloton as financial advisers respectively and expect the transaction to close in Q3 2019.

To learn more about Merck (MRK) and to track its ongoing progress please visit the Vista Partners Merck Coverage Page.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.

week7(9)

Merck to Buy Peloton for Up to $2.2 Billion, Day Before IPO

Merck will pay $1.05 billion in cash, plus $1.15 billion in additional payments based on how the small company’s experimental drugs fare as they are developed further by Merck, the firms said in a statement announcing the deal Tuesday. The deal offers an immediate payout for Peloton’s investors, including..

finance.yahoo.com

Read Full Article


YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us